Most notably, targeted therapeutic delivery of antagomiR-182-5p in pancreatic tumor-bearing mice with varying immunogenic potential results in a significant decrease in tumor volume, increased survival, restoration of M1/M2 ratio, and an overall increase in CD8+ T cell activation in the TME. Here, CD8A is linked to pancreatic neoplasm.